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| INTRODUC TI ON
Lung cancer is the leading cause of cancer-related death around the world. There are approximately 1.30 million new cases and 1.20 million deaths due to lung cancer every year. 1 Non-small-cell lung cancer accounts for approximately 80% of lung cancer cases. 2 Since the beginning of the 21st century, molecular targeting therapies such as EGFR-TKIs have shown promising curative effects in NSCLC patients. However, the overall 5-year survival rate of NSCLC has not apparently been improved due to primary or secondary drug resistance. 3, 4 Therefore, new treatments for lung cancer are urgently needed.
Recently, immunotherapies targeting the PD-1 coinhibitory receptor and its adaptor-programmed death ligand 1 (PD-L1) by mAbs have represented a major breakthrough in the treatment of various advanced tumors, including NSCLC. 5, 6 Programmed cell death-1 belongs to the CD28 family and is a type I transmembrane protein mainly expressed on activated T cells. Its ligand PD-L1 belongs to the B7 family and is widely expressed on dendritic cells, macrophages, activated T and B cells, and non-immune cells including cancer cells. 7, 8 As important immune checkpoint molecules, PD-1/ PD-L1 interaction suppresses the growth and function of effector T cells by inducing T cell apoptosis, anergy, and exhaustion and regulating the secretion of various cytokines. 9, 10 Tumor cells with PD-L1 overexpression have been reported to be related to aggressive behavior and worse disease control and treatment outcomes.
11-13
A growing amount of evidence has elucidated the intrinsic and extrinsic mechanisms of PD-L1 expression regulation in cancer cells. 14 
| MATERIAL S AND ME THODS

| Cell lines and cell culture
The human NSCLC cells H522, H661, HCC827, H1299, HCC2935, H1650, H1792, and H1975 were obtained from ATCC (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin stock in a humidified atmosphere of 5% CO 2 at 37°C.
| Major reagents and Abs
The MEK/ERK inhibitor U0126, PI3K/AKT inhibitor LY294002, NF- 
| Expression vectors and siRNA transfection
Expression vectors containing important EGFR mutants were constructed by subcloning the full coding domain sequence of the EGFR gene with e19del, e19del + T790M, L858R, and L858R + T790M, into the pcDNA3.1-His-Xpress vector (Invitrogen, Carlsbad, CA, USA). All constructs were restriction mapped and sequenced.
Specific siRNA sequences targeting the EGFR gene (si-EGFR) 22, 23 were synthetized by Beijing Aoke Peak Biotechnology (Beijing, China).
Expression vectors and siRNA transfections were carried out as described. 24 Briefly, exponentially growing NSCLC cells were seeded into 
| Flow cytometry
The 
| Pathway inhibition experiment
| Western blot analysis
The treated cells were lysed on ice for 25 minutes using RIPA Lysing
Buffer supplemented with protease inhibitors, and the solution was cleared by centrifugation at 14 000 g for 20 minutes. The total protein concentration was quantified utilizing a BCA protein assay kit, and equal amounts of proteins (20-40 μg/lane) were separated on 10%-12% SDS-PAGE gels and electrotransferred to PVDF membranes. The membranes were then blocked with 5% nonfat milk and probed with specific primary Abs:
anti-His, and anti-Actin (1:1000-1:5000 dilution). After washing with 0.2% Tween 20/PBS buffer 4 times, membranes were incubated with HRP-conjugated secondary Ab and visualized using the ECL system (GE Healthcare, Little Chalfont, UK). 
| In vivo animal model experiment
| Immunohistochemical analysis
For immunohistochemistry analysis of the expression of p-IκBα, HIF-1α, and PD-L1, tumor samples were obtained from 149 NSCLC patients who had undergone surgical resection at Beijing Cancer
Hospital. Tumor tissues obtained from xenotransplanted tumor models were also included. All the specimens had been routinely formalin-fixed, paraffin-embedded, and serially sectioned at 5 μm in thickness.
All tissues were stained using the streptavidin-peroxidase immunohistochemical method. Briefly, the slides were deparaffinized in xylene, rehydrated in graded ethanol, and then treated with PBS containing 3% hydrogen dioxide to block endogenous peroxidase. Slides were preincubated in 10% goat serum to block nonspecific binding and in ≥5%, p-IκBα cytoplasm staining in ≥10%, and HIF-1α nuclear staining in ≥10% of tumor cells were defined as positive results. 25 All NSCLC sections were histopathologically reviewed by 2 trained pathologists.
| DNA extraction and EGFR genotyping
The cancer tissues from all the 149 NSCLC samples were separated using manual microdissection and incubated overnight at 56°C in 50 μL digestion buffer containing 10 mg/mL proteinase K, 0.5% Tween-20, 1 mmol/L EDTA, pH 8.0, and 50 mmol/L Tris, pH 8.5. The next day, proteinase K was inactivated by incubation of the samples at 100°C for 10 minutes. DNA samples were stored at −80°C until analysis. The EGFR status was also determined by PCR direct sequencing using the primers as previously reported. 26 Polymerase chain reaction was carried out using 50 ng each sample DNA as template and negative controls (extracted slices of paraffin blocks containing no tissue) were included. The EGFR status was identified by direct sequencing using the ABI 3700 DNA sequencer (PE Applied Biosystems). 
| Statistical analysis
| RE SULTS
| Activation of EGFR signaling pathway and PD-L1 expression in NSCLC cells
To The percentages of cells with both EGFR and PD-L1 expression on cell surface were 88.9%, 55.8%, and 62.7% in 3 NSCLC cell lines with mutated EGFR (HCC827, HCC2935, and H1975, respectively), which were obviously higher than the remaining NSCLC cell lines carrying WT EGFR ( Figure 1B ).
| Effects of activation or inhibition of EGFR signaling pathway on PD-L1 expression regulation in NSCLC cells
To 
| Correlations among EGFR status, p-IκBα, HIF-1α, and PD-L1 protein levels in NSCLC tissues
The representative examples of p-IκBα, HIF-1α, and PD-L1 staining are shown in Figure 4 Elevated protein levels of p-IκBα and HIF-1α were also detected in tissues carrying EGFR mutants compared to tissues with the WT EGFR gene (56.0% vs 44.0%, P = .029 and 56.4% vs 43.6%, P = .012, respectively; Table 2 ). Additionally, the proportion of tissues with positive p-IκBα staining was significantly higher in NSCLC tissues with HIF-1α positive staining than HIF-1α negative staining (59.2% vs 40.8%; P = .002), as shown in Table 3 . and activation of NF-κB. 47 Hypoxia-inducible factor-1α has also been reported to directly transcript NF-κB expression under hypoxia. 45, 48 Based on previous research reports and our existing research findings,
| D ISCUSS I ON
we developed a possible model for PD-L1 expression regulation by EGFR mutants ( Figure 5 ).
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